STOP CHILDREN'S CANCER INC
Programs
Program 1 [2020]
SINCE ITS INCEPTION IN 1981, STOP CHILDREN'S CANCER HAS RAISED OVER $10 MILLION, INCLUDING THE BONNIE'S LEGACY ENDOWMENT FUND WHICH HAS APPROXIMATELY $1 MILLION IN PERPETUITY. IN ADDITION, AS A RESULT OF THESE DONATIONS, WELL IN EXCESS OF $20 MILLION IN NATIONAL CANCER INSTITUTE/NATIONAL INSTITUTE OF HEALTH (NIH) GRANTS HAVE BEEN AWARDED.RESEARCH FUNDING INCLUDES: STOP CHILDREN'S CANCER / BONNIE R. FREEMAN CLINICAL TRIAL FUNDTHIS FUND HAS CONTINUED TO SUPPORT THE PROGRAM INFRASTRUCTURE, INCLUDING THE SALARY OF DR. GISELLE MOORE-HIGGS WHO HAS LED OUR EFFORTS IN GROWING PEDIATRIC CANCER TRIALS. DESPITE A YEAR FIGHTING COVID, THE PEDIATRIC ONCOLOGY CLINICAL TRIALS TEAM WAS ONE OF THE MOST PRODUCTIVE IN THE CANCER CENTER. THIS INCLUDES ENROLLING 25 CHILDREN ON PEDIATRIC CANCER TREATMENT TRIALS, 67 PATIENTS ON BASIC SCIENCE, SUPPORTIVE CARE, OR SURVIVORSHIP STUDIES, AND AN ADDITIONAL 74 ENROLLED ON THE CHILDREN'S ONCOLOGY GROUP REGISTRY AND BIOLOGY STUDY DURING THE ACADEMIC YEAR.STOP CHILDREN'S CANCER / KIMBERLY H. FLAITZ RESEARCH GRANTTHE FUNDING WAS USED TO SUPPORT THE SALARY OF DR. MATTHEW CASCIO WHO IS WORKING ON DEVELOPING TECHNOLOGIES FOCUSED ON IMPROVING THERAPIES FOR PEDIATRIC BONE TUMORS SUCH AS OSTEOSARCOMA. HIS WORK HAS INCLUDED STUDYING THE MECHANISMS OF A VACCINE TO GANGLIOSIDE 3 WHICH IS EXPRESSED ON OSTEOSARCOMA AND DETERMINING WHAT IMMUNE CELLS ARE CAUSING THESE TUMORS TO RESPOND. IN ADDITION, HE HAS CONTINUED TO DEVELOP CHIMERIC ANTIGEN RECEPTOR T-CELLS FOR OSTEOSARCOMA, ANOTHER WAY TO TREAT THESE TUMORS THAT HAS BEEN PROVEN EFFECTIVE IN OTHER FORMS OF CHILDHOOD CANCER.LYRICS FOR LIFE / STOP CHILDREN'S CANCER JEFFREY A. BLOCK RESEARCH AWARDTHE FUNDING WAS USED TO SUPPORT THE SALARY OF DR. PAUL CASTILLO WHO IS WORKING ON DEVELOPING NOVEL IMMUNOTHERAPIES TO TREAT REFRACTORY CANCERS, ESPECIALLY T CELL LEUKEMIAS AND T CELL LYMPHOMAS. HE IS WORKING ON IDENTIFYING TUMOR TARGETS ONLY EXPRESSED BY TUMOR CELLS AND NOT BY NORMAL CELLS; THUS, NORMAL TISSUES ARE NOT AFFECTED BY THE IMMUNE SYSTEM TRAINED TO RECOGNIZED AND EXQUISITELY KILL MALIGNANT T CELLS. HE HAS ALSO EXPANDED HIS STUDIES TO WORK ON CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS THAT TARGET CD70, A HIGHLY EXPRESSED ANTIGEN IN SEVERAL CANCERS INCLUDING T CELL MALIGNANCIES AND SOLID TUMORS.IT IS THE POLICY OF STOP CHILDREN'S CANCER THAT NO MONIES ARE USED TO PAY OVERHEAD AND ADMINISTRATIVE FEES OF ANY OUTSIDE ORGANIZATIONS. NO MONIES MAY BE USED TO PAY ORGANIZATIONS ENGAGED IN FUNDRAISING OR FOR COSTS INCURRED IN OBTAINING GRANTS.GeographiesNot indicatedDatesJan 1, 2020 – Dec 31, 2020Source990No causes providedNo populations provided–$388.8KStop Children's Cancer Initiatives
SINCE ITS INCEPTION IN 1981, STOP CHILDREN'S CANCER HAS RAISED OVER $7 MILLION, INCLUDING THE BONNIE'S LEGACY ENDOWMENT FUND WHICH HAS APPROXIMATELY $1 MILLION IN PERPETUITY. IN ADDITION, AS A RESULT OF THESE DONATIONS, WELL IN EXCESS OF $18 MILLION IN NATIONAL CANCER INSTITUTE/NATIONAL INSTITUTE OF HEALTH (NIH) GRANTS AND OTHER AWARDS HAVE BEEN AWARDED.STOP CHILDREN'S CANCER / BONNIE R. FREEMAN CLINICAL TRIAL FUND:THIS FUND CONTINUES TO SUPPORT THE PROGRAM INFRASTRUCTURE, INCLUDING THE DIRECTOR'S POSITION WHO HAS LED OUR EFFORTS IN GROWING THE PEDIATRIC CANCER TRIALS. THIS INCLUDES ENROLLING 55 CHILDREN ON PEDIATRIC CANCER TREATMENT TRIALS, 84 PATIENTS ON BASIC SCIENCE, SUPPORTIVE CARE, OR SURVIVORSHIP STUDIES, AND AN ADDITIONAL 64 ENROLLED ON THE CHILDREN'S ONCOLOGY GROUP REGISTRY AND BIOLOGY STUDY DURING THE ACADEMIC YEAR. STOP CHILDREN'S CANCER / KIMBERLY H. FLAITZ RESEARCH GRANT:A KEY GOAL OF THIS RESEARCH FUND WAS TO SUPPORT WORK ON DEVELOPING VACCINES FOR PEDIATRIC OSTEOSARCOMA WITH THE ULTIMATE GOAL OF OPENING A TRIAL USING ONE OF THESE TECHNOLOGIES IN CHILDREN. THE FUNDING CONTINUED TO SUPPORT THE SALARY OF DR. MATTHEW CASCIO WORKING ON DEVELOPING LIPID-NANOPARTICLE(NP) VACCINES AND CAR T CELL IMMUNOTHERAPY. IN PARTNERSHIP WITH DRS. CASCIO AND MILNER (MENTOR), WE HAVE ESTABLISHED A JOINT PEDIATRIC AND LARGE-ANIMAL CANCER IMMUNOTHERAPY PROGRAM. TOGETHER WE HAVE MANUFACTURED CLINICAL GRADE LIPID-NANOPARTICLE VACCINES. IN PET-DOGS WITH SPONTANEOUSLY OCCURRING OSA, WE HAVE SHOWN THAT LIPID-NP VACCINES ELICIT IMMUNE RESPONSES WITH IMPROVING THE DOGS' LONG-TERM SURVIVAL.LYRICS FOR LIFE / STOP CHILDREN'S CANCER JEFFREY A. BLOCK RESEARCH GRANT:THIS FUNDING SUPPORTED DR. PAUL CASTILLO, WHO IS WORKING ON DEVELOPING NOVEL IMMUNOTHERAPIES TO TREAT REFRACTORY CANCERS, ESPECIALLY T-CELL LEUKEMIAS AND T-CELL LYMPHOMAS. GIVEN THE STRIKING RESULTS OF A COMBINATIONAL APPROACH USING CAR T CELLS AND RNA NANOPARTICLE-BASED VACCINES, HE CONTINUES HIS WORK USING THIS APPROACH THAT WAS REPORTED IN 2021. HE HAS SHOWN PROMISING DATA USING THIS IMMUNOTHERAPEUTIC COMBINATIONAL APPROACH FOR ACUTE MYELOID LEUKEMIA, METASTATIC OSTEOSARCOMA, AND METASTATIC MELANOMA. THE PROMISE OF THIS APPROACH IS THAT IT CONTINUES TO HOLD ANTICANCER EFFICACY FOR A WIDE RANGE OF CANCERS. THIS FUNDING ALSO SUPPORTED A REVIEW PAPER THAT WAS PUBLISHED, DESCRIBING TUMOR MODELS FOR EVALUATION OF CAR T CELLS.GeographiesNot indicatedDatesJan 1, 2023 – Dec 31, 2023Source990No causes providedNo populations provided–$437.9K
Copyright 2026. All rights reserved to Chario Inc. (d.b.a. Impala)